Abstract
Tricyclic antidepressants (TCAs) have been usedsuccessfully in the treatment of irritable bowelsyndrome and unexplained chest pain. Little informationis available regarding their use in other functional gastrointestinal disorders. Clinical chartswere analyzed from 37 outpatients (mean age 45 ±2 years, 25 females/12 males) with chronic nausea andvomiting that could not be explained by any conventional organic disorder (mean duration of symptoms 28± 8 months). Twenty-one (57%) had chronicpersistent symptoms; 16 (43%) had intermittent relapsingsymptoms; 13 (35%) also had pain as a dominantcomplaint. Each patient had been treated with TCAsspecifically for the gastrointestinal symptoms(amitriptyline, desipramine, nortriptyline, doxepin, orimipramine), and the subject group was followed for 5.4± 1.1 months. Response (at least moderate symptomreduction using a priori chart rating criteria) occurredin 31 patients (84%), and complete symptom remissionoccurred in 19 (51%)-in 41% with the first TCA trial. Dose at response averaged 50 mg/day,and outcome was unrelated to TCA used. Logisticregression analysis revealed that pain dominanceinterfered with remission (P = 0.03), but other clinical characteristics were not predictive of outcome.This uncontrolled clinical experience indicates that theopen-label response rate of functional nausea andvomiting to low dosages of TCAs resembles that noted in irritable bowel syndrome. TCAs shouldbe studied in controlled fashion for this and relateddyspeptic syndromes, as the success of other treatmentsis limited.
Similar content being viewed by others
REFERENCES
Drossman DA, Thompson WG, Talley NJ, Funch-Jensen P, Janssens J, Whitehead WE: Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int 3: 159–172, 1990
Talley NJ, Phillips SF: Non-ulcer dyspepsia: potential causes and pathophysiology. Ann Intern Med 108: 865–879, 1988
Agreus L, Svardsudd K, Nyren O, Tibblin G: Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 109: 671–680, 1995
Camilleri M, Malagelada JR, Kao PC, Zinsmeister AR: Gastric and autonomic responses to stress in functional dyspepsia. Dig Dis Sci 31: 1169–1177, 1986
Malagelada JR, Stanghellini V: Manometric evaluation of functional upper gut symptoms. Gastroenterology 88: 1223–1231, 1985
Lemann M, Dederding JP, Flourie B, Franchisseur C, Rambaud JC, Jian R: Abnormal perception of visceral pain in response to gastric distention in chronic idiopathic dyspepsia: The irritable stomach syndrome. Dig Dis Sci 36: 1249–1254, 1991
Bradette M, Pare P, Douville P, Morin A: Visceral perception in health and functional dyspepsia: Crossover study of gastric distension with placebo and domperidone. Dig Dis Sci 36: 52–58, 1991
Mayer EA, Raybould HE: Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology 99: 1688–1704, 1990
Gorard DA, Libby GW, Farthing MJG: Effect of a tricyclic antidepressant on small intestinal motility in health and diarrheapredominant irritable bowel syndrome. Dig Dis Sci 40: 86–95, 1995
Clouse RE: Antidepressants for functional gastrointestinal syndrome s. Dig Dis Sci 39: 2352–2363, 1994
Greenbaum DS, Mayle JE, Vanageren LE, et al: Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 32: 257–266, 1987
Cannon RO, Quyyumi AA, Mincemoyer R, Stine AM, Gracely RH, Smith WB, Geraci MF, Black BC, Udhe TW, Waclawiw MA, Maher K, Benjamin SB: Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 330: 1411–1417, 1994
Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities: A double-blind, placebo-controlled trial. Gastroenterology 92: 1027–1036, 1987
Poulsen L, Arendt-Nielsen L, Brosen K, Nielsen KK, Gram LF, Sindrup SH: The hypoalgesic effect of imipramine in different human experimental pain models. Pain 60: 287–293, 1995
Egbunike IG, Chaffee BJ: Antidepressants in the management of chronic pain syndromes. Pharmacotherapy 10: 262–270, 1990
Heefner JD, Russel MW, Wilson ID: Irritable colon and depression. Psychosomatics 19: 540–547, 1978
Abell TL, Kim CH, Malagelada JR: Idiopathic cyclic nausea and vomiting— a disorder of gastrointestinal motility? Mayo Clin Proc 63: 1169–1175, 1988
Clouse RE, Lustman PJ, Geisman RA, Alpers DH: Antidepressant therapy in 138 patients with irritable bowel syndrome: A five-year clinical experience. Aliment Pharmacol Ther 8: 409–416, 1994
Klein KB: Controlled treatment trials in the irritable bowel syndrome: A critique. Gastroenterology 95: 232–241, 1988
Talley NJ, Weaver AL, Zinsmeister AR, Melton JJ 3rd: Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 136: 165–177, 1992
Magni G: The use of antidepressants in the treatment of chronic pain. A review of current evidence. Drugs 42: 730–748, 1991
Rothschild R, Quitkin FM: Review of the use of pattern analysis to differentiate true drug and placebo responses. Psychother Psychosom 58: 203–214, 1992
Mayer EA, Gebhart GF: Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 107: 271–293, 1994
Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R: Effects of desipramine, amitryptiline and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326: 1250–1256, 1992
Watson CPN, Chipman M, Reed K, Evans RJ, Birkett N: Amitryptiline versus maprotiline in postherpetic neuralgia, a randomixed, double blind, crossover trial. Pain 48: 29–36, 1992
Mcquay HJ, Carroll D, Glynn CJ: Low dose amitriptyline in the treatment of chronic pain. Anaesthesia 47: 646–652, 1992
Peghnini P, Katz P, Castell D: Imipramine increase s pain and sensation thresholds to e sophageal balloon distension in humans. Gastroenterology 112: A255, 1997
Gorelick A, Koshy S, Hooper F, Bennett T, Chey WD, Owyand C, Hasler W: Differential inhibitory effects of tricyclic antidepressant agents on pain evoked by nociceptive somatic and viceral stimuli. Dig Dis Sci 41: 1888, 1996 (abstract)
Mitchelson F: Pharmacological agents affecting emesis: A re view (part I). Drugs 43: 295–315, 1992
Mitchelson F: Pharmacological agents affecting emesis: A re view (part II). Drugs 43: 443–463, 1992
Richelson E: Pharmacology of antidepressants in use in the United States. J Clin Psychiatry 43: 4–11, 1982
Clouse RE: Anxiety and gastrointestinal illness. Psych Clin North Am 11: 399–415, 1988
Cole JO: The drug treatment of anxiety and depression. Med Clin North Am 72: 815–830, 1988
Quitkin FM, McGrath PJ, Stewart JW, Taylor BP, Klein DF: Can the effects of antidepressants be observed in the first two weeks of treatment? Neuropsychopharmacology 15: 390–394, 1996
Evans PR, Bennett EJ, Bak Y-T, Tennant CC, Kellow JE: Jejunal sensorimotor dysfunction in irritable bowel syndrome: Clinical and psychosocial features. Gastroenterology 110: 393–404, 1996
Prior A, Sorial E, Sun W, Read NW: Irritable bowel syndrome: Difference s between patients who show rectal sensitivity and those who do not. Eur J Gastroenterol Hepatol 5: 343–349, 1993
Rights and permissions
About this article
Cite this article
Prakash, C., Lustman, P.J., Freedland, K.E. et al. Tricyclic Antidepressants for Functional Nausea and Vomiting (Clinical Outcome in 37 Patients). Dig Dis Sci 43, 1951–1956 (1998). https://doi.org/10.1023/A:1018878324327
Issue Date:
DOI: https://doi.org/10.1023/A:1018878324327